Join our daily newsletter At The Bell to receive exclusive market insights
Syntara (ASX: SNT) has reported encouraging preliminary results from the first tranche of its Phase 2 clinical trial evaluating SNT-4728 in patients with isolated REM Sleep Behaviour Disorder (iRBD), a condition linked to a high risk of developing Parkinson’s disease.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The study found a statistically significant reduction in brain inflammation in the putamen, a region closely associated with Parkinson’s motor symptoms.
Twenty of the 30 receiving SNT-4728 recorded a reduction in inflammation after 12 weeks of treatment. The trial enrolled 41 patients and is the first interventional study designed to directly target neuroinflammation in people with iRBD. Brain inflammation was measured using PET imaging alongside other assessments.
Syntara said the results support its view that SNT-4728 may be modifying disease-related inflammatory pathways rather than simply treating symptoms. The therapy was reported to be safe and well-tolerated, with no treatment-related serious adverse events.
The company believes the findings strengthen the case for SNT-4728 as a first-in-class neuro-targeted anti-inflammatory treatment. A provisional patent application has also been lodged covering the therapy’s use in iRBD.
Further analysis, including additional imaging, biological markers and the complete clinical dataset, is now expected in the third quarter of 2026 and will help Syntara determine the next stage of development.
SNT is up 4.35% today, currently trading at 24cps.
Join the discussion: See what HotCopper users are saying about Syntara Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
